Does Medicare Cover Zepbound? GLP-1 Bridge, Copay, and Access

Medicare does cover Zepbound, but how depends on why it is prescribed. For weight loss, coverage runs through a temporary CMS demonstration called the Medicare GLP-1 Bridge, which launched July 1, 2026, and charges eligible beneficiaries a flat $50 copay per monthly fill. For moderate-to-severe obstructive sleep apnea in adults with obesity, Zepbound may be covered under a beneficiary’s standard Medicare Part D plan, subject to the plan’s formulary and prior authorization rules.

Those are the only two routes. Medicare does not otherwise pay for weight-loss drugs, because a statutory exclusion dating to 2003 still bars it from doing so outside of a specific demonstration or a non-weight-loss indication.

The Medicare GLP-1 Bridge in Brief

The Bridge is a short-term CMS demonstration operating from July 1, 2026, through at least December 31, 2027.¹ It sits outside the standard Part D benefit. Claims do not flow through a beneficiary’s own Part D plan; a single central processor handles prior authorization and pays the pharmacy.

Three GLP-1 drugs are covered when prescribed for weight reduction and maintenance: Wegovy (all formulations), Foundayo (an oral tablet), and Zepbound. The Zepbound coverage comes with a specific limit: only the KwikPen formulation qualifies. Single-dose pens and single-dose vials of Zepbound are excluded from the Bridge, and CMS has not publicly explained the restriction.² If you are currently using the vial or single-dose pen, you would need to switch to the KwikPen to use the program.

What You Pay

The copay is $50 per monthly fill, flat.³ It does not change by Part D benefit phase, does not count toward your Part D deductible, and does not count toward the annual out-of-pocket cap. The Low-Income Subsidy (“Extra Help”) and the Medicare Prescription Payment Plan cannot reduce it. Manufacturer coupons and discount cards do not apply either.⁴

For comparison, Zepbound’s list price without coverage runs roughly $499 to $1,086 per fill depending on dose.⁵ The flat copay is possible because Eli Lilly and Novo Nordisk agreed to supply the Bridge at a net price of $245 per monthly supply.⁶

Who Qualifies for the Bridge

Eligibility has two parts: your Medicare enrollment and your clinical picture.

Enrollment Requirements

You must be enrolled in a standalone Medicare Part D plan or a Medicare Advantage plan that includes drug coverage. Special Needs Plans, employer or union group waiver plans, and LI NET also qualify. If you are in a private fee-for-service plan, a PACE organization, or certain cost-contract plans, you are not eligible unless you also carry a standalone Part D plan.¹

One important exclusion: if your existing Part D plan is already paying for a GLP-1 drug for you, you cannot use the Bridge.³

Clinical Criteria

You must be at least 18 and taking Zepbound for weight reduction along with lifestyle changes such as structured nutrition and physical activity. BMI and health conditions are assessed at the time GLP-1 therapy was initiated, not at the time of application. One of the following must apply:

BMI of 35 or higher, with no additional condition required.
BMI of 30 or higher, plus heart failure with preserved ejection fraction, uncontrolled hypertension (despite two blood pressure medications), or chronic kidney disease at stage 3a or above.
BMI of 27 or higher, plus pre-diabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

People with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (MASH) are not eligible for the Bridge. CMS directs those beneficiaries to their Part D plan, because those diagnoses may already qualify for coverage under the standard benefit.³

How to Get Zepbound Through the Bridge

Coverage is not automatic, but you do not need to change Part D plans to use the program.⁷ A prescribing provider writes a prescription for the Zepbound KwikPen for weight management and submits a prior authorization request directly to the Bridge program’s central processor, attesting that you meet the BMI and health condition criteria. The provider does not have to be enrolled in Medicare, but cannot be on the federal Preclusion List.

Once approved, you fill the prescription at a participating pharmacy, which bills through the Bridge program’s dedicated billing code. You pay $50 at the counter. The transaction will not appear on your standard Part D Explanation of Benefits.⁴

Zepbound for Sleep Apnea Under Standard Part D

Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Because that prescription is not for weight loss, it falls outside the statute that otherwise blocks Medicare from paying for weight-loss drugs, and standard Part D plans can cover it.⁸

Coverage is not guaranteed. Zepbound must be on your specific plan’s formulary, and most plans require prior authorization.⁹ Plans typically expect a confirmed diagnosis of moderate-to-severe obstructive sleep apnea from a sleep study, documentation that the condition is weight-related, and a BMI above 30. Some plans may ask that you try CPAP first, though a prescriber can order both CPAP and Zepbound at the same time.

Costs follow the normal Part D benefit structure. In 2026, you may face your plan’s deductible (up to $615), then cost-sharing in subsequent phases, with total out-of-pocket spending on Part D drugs capped at $2,100 for the year.⁸ You can check whether your plan covers Zepbound using the plan comparison tool at Medicare.gov.

If Zepbound is covered for you under standard Part D for sleep apnea, you cannot also use the Bridge for the same drug. CMS has told plans not to push coverage decisions off their formularies and onto the Bridge.¹

Why Coverage Works This Way

When Congress created Part D in 2003, it carried over a long-standing Medicaid exclusion barring coverage of “agents when used for anorexia, weight loss, or weight gain.” That exclusion, in sections 1860D-2(e)(2) and 1927(d)(2) of the Social Security Act, still sits on the books.¹⁰ CMS finalized its 2026 contract-year rule in April 2025 without a provision that would have reinterpreted the exclusion for obesity drugs.¹¹ That is why the Bridge is a demonstration project rather than a permanent benefit.

What Could Change

CMS has designed a broader voluntary program called the BALANCE Model, under which participating Part D plans would cover GLP-1 drugs for obesity at a negotiated net price of $245 per monthly supply, with capped cost-sharing and manufacturer-funded lifestyle support.⁶ The Medicare Part D side was planned for January 2027, but CMS told Part D sponsors not to indicate BALANCE participation in their 2027 bidding tools, signaling a delay. The Bridge has been extended through at least December 31, 2027, to maintain access in the meantime.¹²

In Congress, the Treat and Reduce Obesity Act has been reintroduced as H.R. 4231 and S. 1973 in the 119th Congress.¹³¹⁴ It would permanently allow Part D plans to cover FDA-approved obesity medications. Versions of the bill have been introduced since 2013 without passage. Until Congress acts, Medicare coverage of Zepbound for weight loss will continue to rest on CMS demonstration authority, which the agency can extend or end.

1
CMS.gov. Medicare GLP-1 Bridge
2
CMS.gov. Medicare GLP-1 Bridge – Information for Part D Plans
3
Medicare.gov. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month
4
Medicare.gov. Weight Loss Drugs
5
Eli Lilly and Company. Zepbound Pricing Information
6
KFF. What To Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
7
CMS.gov. Medicare GLP-1 Bridge – Information for Providers
8
Medical News Today. Is Zepbound Covered by Medicare
9
American Sleep Apnea Association. Does Medicare Cover Zepbound for Sleep Apnea
10
National Library of Medicine. Medicare Coverage of Anti-Obesity Medications
11
Healio. CMS Decision To Remove Obesity Drug Coverage From 2026 Final Rule Disappoints Societies
12
Rise Health. CMS Extends Medicare GLP-1 Bridge, Delays BALANCE in Part D
13
Congress.gov. H.R.4231 – Treat and Reduce Obesity Act of 2025
14
Congress.gov. S.1973 – Treat and Reduce Obesity Act of 2025